Abbott, Abbott Park, Ill, has received an FDA emergency use authorization (EUA) for the company’s molecular test for the novel coronavirus causing the global pandemic covid-19. Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the United States. The tests are used on the company’s m2000 RealTime system.
Abbott will be working with health systems and government authorities to deploy additional m2000 systems where they are needed, and the company is scaling up production at its US manufacturing location to reach capacity for one million tests per week by the end of March.
“A global challenge like coronavirus requires the commitment and cooperation of everyone who has the ability to help address it,” says Miles D. White, chairman and chief executive officer of Abbott. “I’m proud of the Abbott team and what they’ve accomplished in such a short period of time, and I want to thank the administration and FDA for their partnership in making this happen.”
For more information, visit Abbott.
